『Pharmacology News』のカバーアート

Pharmacology News

Pharmacology News

著者： Circle Of Insight Productions
無料で聴く

Join Dr. Carlos on “Pharmacology Insights,” your source for the latest research and news on pharmacology, medications, and street drugs. Each episode delves into cutting-edge discoveries, practical applications, and the evolving landscape of both legal and illicit substances. Gain a deeper understanding of how drugs work, their impacts on health, and the latest trends in medication and drug use. Tune in for expert analysis and insightful discussions that keep you informed on all things pharmacological.Copyright Circle Of Insight Productions 社会科学 科学 経済学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Psychopharmacology Masterclass: Drug Classes, Mechanisms of Action, and What Every Psychologist Needs to Know for Clinical Practice and the

    Psychopharmacology Masterclass: Drug Classes, Mechanisms of Action, and What Every Psychologist Needs to Know for Clinical Practice and the
    2026/06/24
    Psychopharmacology is one of the most heavily tested and clinically consequential domains in professional psychology, covering everything from the neurochemical mechanisms behind antidepressants, antipsychotics, mood stabilizers, and anxiolytics to the pharmacokinetic principles that determine how drugs are absorbed, distributed, metabolized, and eliminated in ways that directly affect treatment outcomes and patient safety. This lecture-style episode breaks down the major drug classes tested on the EPPP and encountered in integrated care settings, including SSRIs, SNRIs, tricyclics, MAOIs, first and second generation antipsychotics, benzodiazepines, and lithium, covering their mechanisms, therapeutic windows, side effect profiles, and the clinical decision-making frameworks psychologists need to consult competently with prescribing professionals. Whether you are preparing for licensure, refreshing your pharmacology knowledge for supervision or consultation, or building the scientific foundation you need to practice in an era of increasingly integrated behavioral health care, this episode delivers the core content in a focused, high-yield format designed to make complex neuroscience and pharmacology accessible and retainable.
    続きを読む 一部表示
    17 分
  • Retracted: The Hepatitis B Vaccine, Autism Claims, and the Challenges of Causation

    Retracted: The Hepatitis B Vaccine, Autism Claims, and the Challenges of Causation
    2026/06/09
    In this episode, we examine the recent retraction of a 2010 study that suggested a link between neonatal hepatitis B vaccination and autism in boys. We break down the methodological flaws that led to its withdrawal, explore related research from the same authors and others, and dive into why establishing causal links between vaccines and autism remains extraordinarily complex. Autism is multifactorial—shaped by genetics, environment, and timing—and we discuss the broader scientific consensus while highlighting the importance of rigorous evidence in public health debates.
    続きを読む 一部表示
    7 分
  • Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”

    Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”
    2026/06/08
    In 2023, the FDA approved escitalopram (Lexapro) for generalized anxiety disorder (GAD) in children aged 7 and older, based largely on one industry-sponsored trial showing a small statistical edge over placebo on the Pediatric Anxiety Rating Scale (PARS). Critics argue the benefits fall below clinically meaningful thresholds while risks—particularly a roughly six-fold increase in treatment-emergent suicidal ideation—raise serious concerns about the risk-benefit balance. This episode explores the trial data, study limitations, broader context of pediatric antidepressant use, and what it means for families and clinicians navigating anxiety treatment options.
    続きを読む 一部表示
    8 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません